IPP Bureau
IPP organizes session on "Combating Heat Exchanger Tube Corrosion in Pharma and Chemical Industry" on October 15 at Sheraton Hyderabad Hotel
By IPP Bureau - October 13, 2025
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
By IPP Bureau - October 13, 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
By IPP Bureau - October 13, 2025
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Roche to present latest cancer care data at ESMO 2025
By IPP Bureau - October 13, 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025
By IPP Bureau - October 13, 2025
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Cadila launches allergy relief tablet Dlorfast-M
By IPP Bureau - October 13, 2025
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
By IPP Bureau - October 13, 2025
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
By IPP Bureau - October 12, 2025
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Samsung Biologics introduces optimized manufacturing framework ‘ExellenS’
By IPP Bureau - October 12, 2025
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
AstraZeneca to lower cost of medicines for American patients
By IPP Bureau - October 12, 2025
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
By IPP Bureau - October 12, 2025
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Merck unveils new HIV treatment and prevention data at EACS 2025
By IPP Bureau - October 12, 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
By IPP Bureau - October 11, 2025
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Merck advances cancer innovation by expanding role of Keytruda across new tumor
By IPP Bureau - October 11, 2025
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium
By IPP Bureau - October 11, 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
